Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $35.8 million versus the consensus estimate of $34.1 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.